Columnist Sam Kirton pays tribute to his friend and IPF mentor, Pieter van den Assum, who passed away on May 17.

LTI-03 is formulated as a dry powder inhalation therapy that's designed to help ease fibrosis and symptoms of idiopathic ...

Pulmonary fibrosis (PF) is a respiratory condition that causes the formation of scar tissue in the lungs. It is progressive disease and can take years to progress. Because of thickening lung tissue, ...

GRI Bio reached an interim enrollment goal for a clinical trial testing GRI-0621, a therapy targeting natural killer T-cells ...

A cancer immunotherapy known as ipilimumab was able to reduce scar formation and promote tissue regeneration in the lungs of a mouse model of idiopathic pulmonary fibrosis (IPF). Treatment boosted the ...

The abnormal accumulation of immune plasma cells in the lungs — and their subsequent generation of damaging antibodies — may be a key driver of idiopathic pulmonary fibrosis (IPF), according to new ...

Basal stem cells taken from the upper part of a patient’s respiratory tract can be expanded in the lab and then transplanted back into their lungs to treat idiopathic pulmonary fibrosis (IPF), ...

Pliant Therapeutics has discontinued a pivotal Phase 2b/3 clinical trial evaluating its idiopathic pulmonary fibrosis (IPF) treatment bexotegrast due to safety issues. The BEACON-IPF (NCT06097260) ...

Do you ever have one of those days? You know the kind: Nothing seems to go your way and the day ends with a huge sigh. When I was diagnosed with idiopathic pulmonary fibrosis, I learned that not every ...